Benevolent AI (Benevolent AI) Days Payable : 0.00 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Benevolent AI Days Payable?

Benevolent AI's average Accounts Payable for the three months ended in Dec. 2023 was $2.91 Mil. Benevolent AI's Cost of Goods Sold for the three months ended in Dec. 2023 was $0.00 Mil.

The historical rank and industry rank for Benevolent AI's Days Payable or its related term are showing as below:

BAIVF's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.01
* Ranked among companies with meaningful Days Payable only.

Benevolent AI's Days Payable stayed the same from Dec. 2021 (0.00) to Dec. 2023 (0.00). stayed the same

Benevolent AI Days Payable Historical Data

The historical data trend for Benevolent AI's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benevolent AI Days Payable Chart

Benevolent AI Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

Benevolent AI Quarterly Data
	Dec18	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Days Payable	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Benevolent AI's Days Payable

For the Biotechnology subindustry, Benevolent AI's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Benevolent AI's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benevolent AI's Days Payable distribution charts can be found below:

* The bar in red indicates where Benevolent AI's Days Payable falls into.

Benevolent AI Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Benevolent AI's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (4.358	+	2.887)	/	2 )	/	0	*	365
=	3.6225					/	0	*	365
=	N/A

Benevolent AI's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (2.927	+	2.887)	/	2 )	/	0	*	365 / 4
=	2.907					/	0	*	365 / 4
=	N/A

Benevolent AI Days Payable Related Terms

Thank you for viewing the detailed overview of Benevolent AI's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Benevolent AI (Benevolent AI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benevolent AI (GREY:BAIVF) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

BAI:Netherlands 2XA:Germany

Address

4-8 Maple Street, London, GBR, W1T 5HD

Website

https://www.benevolent.com

Benevolent AI is a clinical-stage AI-enabled drug discovery company. It delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies.